Urology AI scribe 2026: PSA tracking, prostate cancer active surveillance, stone disease, cystoscopy, and the specialty workflow

May 8, 2026 · 6 min read

Urology documents across five visit modes: office E/M with PSA trend interpretation, prostate cancer active surveillance, stone disease management, cystoscopy procedure notes, and major surgical procedures (robotic prostatectomy, cystectomy, partial nephrectomy). Each has specialty workflow patterns general AI scribes don't capture cleanly.

The 2026 urology-aware AI scribe stack handles four things general scribes miss: PSA trend integration with risk stratification, prostate cancer active surveillance documentation, stone composition analysis tracking, and cystoscopy structured findings.

PSA tracking and risk stratification

PSA trends drive prostate cancer screening, biopsy decisions, and surveillance. The AI scribe should:

• Pull last 5-10 PSA values with dates
• Compute PSA velocity, doubling time
• Surface free PSA / PSA isoforms (PHI, 4Kscore) if measured
• Cross-reference DRE findings, prior biopsy results, MRI PI-RADS
• Risk stratification (NCCN very low / low / intermediate-favorable / intermediate-unfavorable / high / very high) for known cancer
• Active surveillance protocol element tracking (PSA cadence, MRI cadence, biopsy schedule)

The urology-aware system prompt

You are documenting a urology encounter.

OUTPUT structured note based on visit type:

For office E/M:
1. Subjective: by anatomic / functional system (LUTS, hematuria, sexual, pain, incontinence, fertility)
2. Symptom scoring (IPSS, IIEF, ICIQ as applicable)
3. Objective: GU exam, DRE if performed
4. Lab review: PSA trend, urinalysis/culture, BMP/Cr, testosterone if applicable
5. Imaging review: ultrasound, CT, MRI prostate (PI-RADS)
6. Assessment by problem with ICD-10 specificity
7. Plan

For prostate cancer surveillance:
- Risk category and inclusion criteria
- PSA cadence + last value vs prior
- DRE cadence + last finding
- MRI cadence + last PI-RADS
- Biopsy schedule and last finding
- Trigger criteria for treatment (any progression flag)

For stone disease:
- Stone burden (size, side, location)
- Composition analysis if available
- 24-hour urine if collected
- Metabolic workup
- Treatment plan (medical expulsion / lithotripsy / ureteroscopy / PCNL)
- Recurrence prevention plan

For cystoscopy:
- Indication
- Findings: urethra, prostate (if male), bladder mucosa, ureteral orifices
- Tumors: size, location, appearance, biopsy taken
- Stones / foreign body if present
- Voiding function if dynamic study performed

For procedures (TURBT, ureteroscopy, etc.):
- Standard op note structure
- Anatomic detail
- Specimens sent
- Catheter placement
- Discharge plan

Cite transcript or trend data. For active surveillance, ensure all protocol elements are documented for protocol adherence audit.

Stone disease metabolic workup

Recurrent stone formers need 24-hour urine analysis with structured documentation:

• Volume, pH, calcium, oxalate, citrate, sodium, uric acid, magnesium
• Comparison to lithogenic risk thresholds
• Composition analysis if stone retrieved (calcium oxalate / phosphate / uric acid / cystine / struvite)
• Targeted prevention plan based on metabolic profile

Vendor and DIY paths

For urology practices: native specialty EHRs (NextGen Urology, others) have ambient AI. The DIY stack with PSA trend pull and active surveillance protocol tracking outperforms general scribes for the prostate cancer surveillance use case especially.

BAA chain

Practice + EHR + lab vendor + imaging vendor + stone composition lab (Beck, Litholink) + transcription vendor + LLM vendor.

When to start

For urology practices with active surveillance prostate cancer panels, the protocol-element tracking is high-leverage — missed PSA cadence or biopsy schedule is a documented quality gap. The DIY stack is buildable in 4-6 weeks.